{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"OR is defined as participants with CR or PR.","groups":[{"description":"Participants with Relapsed/Refractory Richter Transformation received the following treatment during the study:\n\nLymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG000","title":"Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel"}],"populationDescription":"Data not available since Substudy B was terminated early and central committee was not formed and central assessment was not conducted, therefore, data is not available for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Substudy B: Number of Participants With OR Based on Clonal Relationship to the Underlying CLL by Central Assessment Per the Lugano Classification","type":"SECONDARY"}